全文获取类型
收费全文 | 1512796篇 |
免费 | 88717篇 |
国内免费 | 3197篇 |
专业分类
耳鼻咽喉 | 20698篇 |
儿科学 | 49478篇 |
妇产科学 | 41932篇 |
基础医学 | 227717篇 |
口腔科学 | 40296篇 |
临床医学 | 129154篇 |
内科学 | 290881篇 |
皮肤病学 | 32870篇 |
神经病学 | 110151篇 |
特种医学 | 61931篇 |
外国民族医学 | 442篇 |
外科学 | 231661篇 |
综合类 | 26841篇 |
现状与发展 | 2篇 |
一般理论 | 347篇 |
预防医学 | 111378篇 |
眼科学 | 34267篇 |
药学 | 110712篇 |
3篇 | |
中国医学 | 2878篇 |
肿瘤学 | 81071篇 |
出版年
2018年 | 17066篇 |
2017年 | 14075篇 |
2016年 | 14684篇 |
2015年 | 17575篇 |
2014年 | 22172篇 |
2013年 | 31087篇 |
2012年 | 47586篇 |
2011年 | 46229篇 |
2010年 | 27044篇 |
2009年 | 26639篇 |
2008年 | 41391篇 |
2007年 | 45074篇 |
2006年 | 45003篇 |
2005年 | 51441篇 |
2004年 | 51503篇 |
2003年 | 45989篇 |
2002年 | 40665篇 |
2001年 | 63080篇 |
2000年 | 62711篇 |
1999年 | 55953篇 |
1998年 | 14863篇 |
1997年 | 13057篇 |
1996年 | 13068篇 |
1995年 | 12270篇 |
1994年 | 11479篇 |
1992年 | 45349篇 |
1991年 | 45509篇 |
1990年 | 45308篇 |
1989年 | 43845篇 |
1988年 | 40548篇 |
1987年 | 39943篇 |
1986年 | 37973篇 |
1985年 | 35983篇 |
1984年 | 26592篇 |
1983年 | 22571篇 |
1982年 | 12500篇 |
1979年 | 25367篇 |
1978年 | 17602篇 |
1977年 | 14531篇 |
1976年 | 14157篇 |
1975年 | 16684篇 |
1974年 | 19568篇 |
1973年 | 18604篇 |
1972年 | 17640篇 |
1971年 | 16659篇 |
1970年 | 15818篇 |
1969年 | 14872篇 |
1968年 | 14032篇 |
1967年 | 12870篇 |
1966年 | 11541篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
15.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
16.
17.
18.
Xiaoyan Lu Isabelle R. Miousse Sandra V. Pirela Jodene K. Moore Stepan Melnyk 《Nanotoxicology》2016,10(5):629-639
Evidence continues to grow on potential environmental health hazards associated with engineered nanomaterials (ENMs). While the geno- and cytotoxic effects of ENMs have been investigated, their potential to target the epigenome remains largely unknown. The aim of this study is two-fold: 1) determining whether or not industry relevant ENMs can affect the epigenome in vivo and 2) validating a recently developed in vitro epigenetic screening platform for inhaled ENMs. Laser printer-emitted engineered nanoparticles (PEPs) released from nano-enabled toners during consumer use and copper oxide (CuO) were chosen since these particles induced significant epigenetic changes in a recent in vitro companion study. In this study, the epigenetic alterations in lung tissue, alveolar macrophages and peripheral blood from intratracheally instilled mice were evaluated. The methylation of global DNA and transposable elements (TEs), the expression of the DNA methylation machinery and TEs, in addition to general toxicological effects in the lung were assessed. CuO exhibited higher cell-damaging potential to the lung, while PEPs showed a greater ability to target the epigenome. Alterations in the methylation status of global DNA and TEs, and expression of TEs and DNA machinery in mouse lung were observed after exposure to CuO and PEPs. Additionally, epigenetic changes were detected in the peripheral blood after PEPs exposure. Altogether, CuO and PEPs can induce epigenetic alterations in a mouse experimental model, which in turn confirms that the recently developed in vitro epigenetic platform using macrophage and epithelial cell lines can be successfully utilized in the epigenetic screening of ENMs. 相似文献
19.
F. Fruzzetti G. Palla A. Sbrana T. Simoncini M. R. Sessa 《Gynecological endocrinology》2020,36(10):938-940
AbstractObjective: To understand the origin of extremely high gonadotropin levels in a perimenopausal woman.Methods: A 52-year-old woman with a 2?months of amenorrhea followed spontaneous menstrual cycles recovery was referred to our outpatient clinic with elevated follicle-stimulating hormone (FSH, 483 mUI/ml), luteinizing hormone (LH, 475 mUI/ml) and prolactin (PRL, 173?ng/ml). She was known to take levosulpiride. The gonadotropin levels did not fit with the clinical features.Results: A gonadotroph tumor was ruled out. Further analysis confirmed constantly high FSH, LH and PRL levels. The measurements were repeated using different analytical platforms with different results. After serial dilutions, nonlinearity was present suggesting an immunoassay interference. After post-polyethylene glycol recovery, hormone levels appeared in the normal range. Anti-goat antibodies were recognized in the serum of the patient.Conclusions: This case report shows a case of falsely abnormal high gonadotropin and PRL levels in a woman during menopause transition. In the clinical practice the evaluation of gonadotropin profile is not recommended at this age, but the abnormal levels stimulated further evaluation. An interference in the assay due to anti-goat antibodies resulted in abnormally high level of FSH and LH. A strict collaboration between clinicians and the laboratory is needed, when laboratory findings do not correspond to clinical findings. 相似文献
20.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600